CHU d'Estaing
- Address
- lock Available on a paid plan
CHU d'Estaing - Gastrointestinal Oncology and Inflammatory Bowel Disease Center
CHU d'Estaing is a leading academic medical center with specialized expertise in gastrointestinal disorders and oncology. The center conducts advanced clinical research focusing on innovative therapeutic approaches for complex digestive system conditions, ranging from chronic inflammatory diseases to advanced malignancies.
- Post-operative management and prevention of recurrence in Crohn's disease
- Advanced metastatic colorectal cancer treatment strategies
- Novel immunotherapy and targeted biologic interventions
The center's research portfolio emphasizes both inflammatory bowel disease and gastrointestinal malignancies, with particular focus on endoscopic assessment methodologies and combination therapy approaches. Current investigations include phase I/II trials evaluating anti-IL-1α antibodies in metastatic settings and preventive strategies for Crohn's disease post-surgical recurrence, utilizing sophisticated endoscopic scoring systems such as the modified Rutgeerts score to assess treatment efficacy.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 4 therapeutic areas and 15 of 40 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 9 by active trials.
lock +8 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in CHU d'Estaing
lock Showing 1 of 14 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Comparison of Apixaban, Rivaroxaban, and Acetylsalicylic Acid for Thromboembolic Prevention in JAK2V617F-Positive Myeloproliferative Neoplasms | Centre Hospitalier Regional Et Universitaire De Brest | Phase IV | Recruiting | Aug 2024 | — |
IMP list
lock Showing 1 of 40 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Fluorouracil | 5 | Unknown | 2014-12-23 | 2024-10-18 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.